Reach Solutions Reach Helpdesk Global regulatory compliance helpdesk Reach Solutions Reach Helpdesk

Human Use

Directive 2001/83/EC relating to medicinal products for human use

This Directive establishes a Community code which brings together all the provisions governing the placing on the market, production, labelling, classification, distribution and advertising of medicinal products for human use.

Scope
The code applies to all medicinal products for human use, except for:

  • Medicinal products prepared in a pharmacy in accordance with a medical prescription (‘magistral formula’);
  • Medicinal products prepared in a pharmacy in accordance with the prescriptions of a pharmacopoeia (‘officinal formula’);
  • Medicinal products intended for research and development trials;
  • Intermediate products intended for further processing;
  • Radionuclides in the form of sealed sources;
  • Whole blood, plasma or blood cells of human origin.

Manufacture and importation

The following operations are subject to authorisation by the Member States:

  • Manufacture, dividing up, packaging or presentation of medicinal products within the territories of the Member States (with the exception of operations performed by a pharmacist solely for retail supply);
  • All imports of medicinal products from Non-EU Member Countries.

Marketing authorization procedure
No medicinal product (with the exception, under certain conditions, of radiopharmaceuticals prepared at the time of use) may be placed on the market of a Member State unless an authorisation has been issued by the competent authorities of that Member State or by the European Medicines Agency (the ‘Agency’).
Only applicants established in the Community may be granted a marketing authorisation.

Documentation required:
Certain particulars and documents must be included with the authorisation request, including :

  • The name and constituents of the medicinal product.
  • The manufacturing method.
  • Therapeutic indications, contra-indications and side-effects.
  • Posology.
  • method and route of administration.
  • Expected shelf-life.
  • Precautionary and safety measures during storage and administration of the medicinal product and disposal of waste.
  • The risk to the environment.
  • A description of control tests employed by the manufacturer.
  • The results of pharmaceutical, pre-clinical and clinical tests, and
  • A copy of any marketing authorization obtained in another Member State or non-member country.

Quotes from Companies

Your Nagpur Team has always provided polite professional,prompt and importantly competent advice and action. Instills confidence in the confidentialit...

Thanks for your valued & timely support.....

We are very much appreciating your so fast response and nice support for providing us these documents.....

Thank you Dr Datta. This makes life simple.
....

First of all I would like to congratulate you and your prestigious organisation on the grand success of REACH symposium held on 7th and 8th of April i....

We attended the Symposium on REACH on 8th April, 2011. Many things have got clarified there. Entire program was nice and successful.....

Thanks for the informative presentation on REACH (about the REACH Symposium held at Mumbai)....

Informative and useful Symposium on REACH Regulation.....

Thanks for your extended cooperation towards REACH Registration.....

The (IUCLID Training) session was very well prepared with good presentation and supporting documentation. Learning by ‘doing’ is put into applicat....

Many thanks for your email, giving the technical Updates on REACH Compliance and information on Letter of Access (LOA). We have found the information ....

Thank you for all the support given by you and your professional team through out the first introduction/awareness seminar of REACH till pre-registrat....

Our experience of working with REACH Support officials has been very cordial, informative and supportive. We look forward for a long association with ....

Thanks for providing valuable updates during the course of discussions in Mumbai....

Thank you for completing the registration of our substances well on time. We count on your support for registration of our substances in next slab as ....

I thank the complete REACH support team for the great work and cooperation. It has been a great learning experience for me and our company. I look for....